Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 20/20 | 1.00 |
| ▸ | AKR1B1 | P15121 | 8/20 | 0.69 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6527321 | 0.93 | PTGDR2 (0.87) | PTGDR2AKR1B1SLC6A4CYP2C9 | |
| SCHEMBL6512615 | 0.92 | PTGDR2 (0.85) | PTGDR2AKR1B1SLC6A4CYP2C9 | |
| SCHEMBL6512642 | 0.91 | PTGDR2 (0.84) | PTGDR2AKR1B1SLC6A4CYP2C9 | |
| SCHEMBL6519008 | 0.91 | PTGDR2 (0.84) | PTGDR2AKR1B1SLC6A4CYP2C9 | |
| SCHEMBL6519941 | 0.89 | PTGDR2 (0.80) | PTGDR2AKR1B1SLC6A4CYP2C9 | |
| SCHEMBL4902353 | 0.88 | PTGDR2 (0.79) | PTGDR2AKR1B1SLC6A4CYP2C9 | |
| SCHEMBL6509653 | 0.88 | PTGDR2 (0.79) | PTGDR2AKR1B1SLC6A4CYP2C9 | |
| SCHEMBL6509675 | 0.87 | PTGDR2 (0.77) | PTGDR2AKR1B1SLC6A4CYP2C9 | |
| SCHEMBL6510974 | 0.87 | PTGDR2 (0.77) | PTGDR2AKR1B1SLC6A4CYP2C9 | |
| SCHEMBL6511175 | 0.86 | PTGDR2 (0.76) | PTGDR2AKR1B1SLC6A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027092-A1 | 1-Acetic Acid-Indole, -Indazole and -Benzimidazole Derivatives Useful for the Treatment of Respiratory Disorders | ASTRAZENECA AB (SE) | 2008-01-31 | — | — | US | claimed |
| WO-2005121141-A1 | PYRROLOPYRIDINE DERIVATIVES AND USE THEREOF FOR TREATING DISEASES MEDIATED BY PROSTAGLANDIN D2 (PGD2) | OXAGEN LIMITED (GB) | 2005-12-22 | — | — | WO | claimed |
| US-20080027092-A1 | 1-Acetic Acid-Indole, -Indazole and -Benzimidazole Derivatives Useful for the Treatment of Respiratory Disorders | ASTRAZENECA AB (SE) | 2008-01-31 | — | — | US | disclosed |
| US-20080027092-A1 | 1-Acetic Acid-Indole, -Indazole and -Benzimidazole Derivatives Useful for the Treatment of Respiratory Disorders | ASTRAZENECA AB (SE) | 2008-01-31 | — | — | US | disclosed |
| US-20080027092-A1 | 1-Acetic Acid-Indole, -Indazole and -Benzimidazole Derivatives Useful for the Treatment of Respiratory Disorders | ASTRAZENECA AB (SE) | 2008-01-31 | — | — | US | disclosed |
| EP-1699781-A1 | 1-ACETIC ACID-INDOLE, -INDAZOLE AND -BENZIMIDAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF RESPIRATORY DISORDERS | AstraZeneca AB (SE) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005121141-A1 | PYRROLOPYRIDINE DERIVATIVES AND USE THEREOF FOR TREATING DISEASES MEDIATED BY PROSTAGLANDIN D2 (PGD2) | OXAGEN LIMITED (GB) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005054232-A1 | 1-ACETIC ACID-INDOLE, -INDAZOLE AND-BENZIMIDAZOLE DERIVATIVES USFUL FOR THE TREATMENT OF RESPIRATORY DISORDERS | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027092-A1 | 1-Acetic Acid-Indole, -Indazole and -Benzimidazole Derivatives Useful for the Treatment of Respiratory Disorders | IDO1, ABAT, ECI1 | PTGDR2 736/4885AKR1B1 53/4885SLC6A4 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.